MedTrace Logo

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

NCT05338762 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 218

Last updated 2022-08-11

No results posted yet for this study

Summary

The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test.

When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.

Conditions

  • SARS-CoV2 Infection

Sponsors & Collaborators

  • Syntactx

    collaborator NETWORK

  • MiCo BioMed Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jay Hahn, PhD · MiCo BioMed

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2021-11-15
Completion
2022-08-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05338762 on ClinicalTrials.gov